Intellectual Property News and Reports

Dr. Reddy’s Laboratories S.A. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) petitioned for inter partes review of U.S. Patent 9,687,454 (the “’454 patent”), owned by Indivior UK Limited (“Indivior”). The United States Patent and Trademark Office Patent Trial and Appeal... Read more →

In September 2007, Galperti S.r.l. (Galperti-Italy), to support its application to the Patent and Trademark Office (PTO) for registration of the mark GALPERTI, told the PTO that, in the five preceding years, its use of the mark was “substantially exclusive.”... Read more →

Apple Inc. (“Apple”) appeals four decisions of the Patent Trial and Appeal Board (“Board”) determining that claims of patents owned by Qualcomm Inc. (“Qualcomm”) weren’t proven unpatentable. This is the second such dispute to reach us since these parties settled... Read more →

Quest Diagnostics Incorporated petitions for a writ of mandamus directing the United States District Court for the Western District of Texas to transfer this case to the United States District Court for the Central District of California. Ravgen, Incorporated opposes.... Read more →

ROHM Semiconductor USA, LLC (“ROHM USA”) appeals from the U.S. District Court for the Northern District of California’s decision compelling arbitration and dismissing ROHM USA’s declaratory judgment action without prejudice. ROHM Semiconductor USA, LLC v. MaxPower Semiconductor, Inc., No. 20-CV-06686-VC,... Read more →

The Brooklyn Brewery Corporation (“Brewery”) appeals a decision of the Trademark Trial and Appeal Board (the “Board”). Brewery petitioned to cancel Brooklyn Brew Shop, LLC’s (“BBS”) registration of the mark “BROOKLYN BREW SHOP,” in standard characters, for goods identified as... Read more →

University of Strathclyde appeals from a final written decision of the Patent Trial and Appeal Board holding claims 1–4 of U.S. Patent No. 9,839,706 unpatentable as obvious. Because neither the Board’s finding that the prior art disclosed all claim limitations... Read more →

This is a case about venue and pleading under the Hatch-Waxman Act. Celgene Corporation (“Celgene”) markets pomalidomide as a multiple-myeloma drug under the brand name Pomalyst. It has patents related to that drug, but many drug companies viewed the validity... Read more →